WO2023110700 - DIHYDROFUROPYRIDINE DERIVATIVES AS RHO-KINASE INHIBITORS
National phase entry is expected:
Publication Number
WO/2023/110700
Publication Date
22.06.2023
International Application No.
PCT/EP2022/085286
International Filing Date
12.12.2022
Title **
[English]
DIHYDROFUROPYRIDINE DERIVATIVES AS RHO-KINASE INHIBITORS
[French]
DÉRIVÉS DE DIHYDROFUROPYRIDINE UTILISÉS COMME INHIBITEURS DE LA RHO-KINASE
Applicants **
CHIESI FARMACEUTICI S.P.A.
Inventors
ACCETTA, Alessandro
RANCATI, Fabio
PALA, Daniele
PASQUA, Adele Elisa
CLARK, David Edward
EDWARDS, Christine
KAPADNIS, Prashant Bhimrao
Priority Data
21213944.8
13.12.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3014 | |
| EPO | Filing, Examination, Granting | 19450 | |
| Japan | Filing, Examination, Granting | 2766 | |
| South Korea | Filing, Examination, Granting | 3127 | |
| USA | Filing, Examination, Granting | 23540 |
Total:
51,897
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).[French]
L'invention concerne des composés de formule (I) inhibant la Rho kinase qui sont des dérivés de dihydrofuropyridine, des procédés de préparation de tels composés, des compositions pharmaceutiques les contenant et leur utilisation thérapeutique. En particulier, les composés de l'invention peuvent être utiles dans le traitement de nombreux troubles associés à des mécanismes d'enzymes ROCK, y compris des maladies pulmonaires telles que l'asthme, la maladie pulmonaire obstructive chronique (MPOC), la fibrose pulmonaire idiopathique (FPI) et l'hypertension artérielle pulmonaire (HTAP).